Date of event, implant date: dates estimated.The patient deaths and device malfunctions referenced will be filed under separate medwatch report #s.The device was not returned for analysis.The lot history record (lhr) for this product could not be reviewed and a similar complaint query could not be performed because the product was not returned for evaluation and the part and lot numbers were not reported.A definitive cause for the reported stenosis, occlusion, pseudoaneurysm and amputation and the relationship to the product, if any, cannot be determined.The reported patient effects of stenosis, occlusion, pseudoaneurysm, and amputation are listed in the supera instructions for use as known potential patient effects associated with the use of the device.Based on the information reported through the research article, a definitive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported unexpected medical intervention and hospitalization were likely related to case circumstances.There is no indication of a product quality issue with respect to manufacture, design or labeling.The udi is unknown as the part and lot numbers were not provided.Article title: a midterm analysis of patients who received femoropopliteal helical interwoven nitinol stents.
|
It was reported through a research article identifying supera that may be related to the following: patient death, restenosis, occlusion, pseudoaneurysm, elongation, malposition, amputation, revascularization, and rehospitalization.This article summarizes clinical outcomes of 315 patients that were treated with supera stents.Specific patient information is documented as unknown.Details are listed in the attached article, titled "a midterm analysis of patients who received femoropopliteal helical interwoven nitinol stents.".
|